edema, arthralgia, elevated blood glucose, etc.), it is typically undesired and many times contraindicated
Additionally, study participants self-reported dietary intake daily, although there was close monitoring of intake through the return of empty food packaging/containers of consumed food and daily monitoring by investigators and weekly meetings with a registered dietitian
Other GLP-1R/GIPR co-agonists such as Cpd86 (Eli Lilly), ZP-DI-70 (Zealand) and NN9709/MAR709 (Novo Nordisk/Marcadia) have also been designed and tested in preclinical models of obesity and subsequently advanced to clinical trials (Table 1)
Treatment of hypertension during pregnancy as a replacement for ACE inhibitors & ARBs The patient can be switched back to an ACE inhibitor or ARB once pregnancy is over Notes: Methyldopa is the L-isomer of alpha-methyldopa References: Benowitz NL (2024): Antihypertensive Agents (Chapter 11)
Microdosing is interesting but untested